콘텐츠로 건너뛰기
Merck
  • Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice.

Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice.

International journal of molecular sciences (2021-07-03)
Patrizia Garbati, Raffaella Barbieri, Matilde Calderoni, Francesca Baldini, Mario Nizzari, Paola Modesto, Tullio Florio, Aldo Pagano
초록

High-risk neuroblastoma (HR-NB) still remains the most dangerous tumor in early childhood. For this reason, the identification of new therapeutic approaches is of fundamental importance. Recently, we combined the conventional pharmacological approach to NB, represented by cisplatin, with fendiline hydrochloride, an inhibitor of several transporters involved in multidrug resistance of cancer cells, which demonstrated an enhancement of the ability of cisplatin to induce apoptosis. In this work, we co-administrated acetazolamide, a carbonic anhydrase isoform IX (CAIX) inhibitor which was reported to increase chemotherapy efficacy in various cancer types, to the cisplatin/fendiline approach in SKNBE2 xenografts in NOD-SCID mice with the aim of identifying a novel and more effective treatment. We observed that the combination of the three drugs increases more than twelvefold the differences in the cytotoxic activity of cisplatin alone, leading to a remarkable decrease of the expression of malignancy markers. Our conclusion is that this approach, based on three FDA-approved drugs, may constitute an appropriate improvement of the pharmacological approach to HR-NB.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Anti-Disialoganglioside GD2 Antibody, clone 14G2a, clone 14.2Ga, Chemicon®, from mouse